[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639031":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":21,"locations":27,"responsibleParty":43,"collaborators":10,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":10,"maxAge":10,"enrollmentInfo":56,"targetDuration":10,"studyType":59,"phases":10,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":30,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Karolinska Institutet","OTHER",[8,12,15,18],{"label":9,"type":10,"description":11,"interventionNames":10},"MCI",null,"The MCI group consists of participants diagnosed with mild cognitive impairment (MCI), in accordance with clinical consensus criteria. This can be of MCI-Lewy body type, MCI-Alzheimer´s disease type, MCI-Parkinson´s disease type, or MCI-other type",{"label":13,"type":10,"description":14,"interventionNames":10},"DLB","The DLB group consists of participants diagnosed with dementia with Lewy bodies (DLB) according to clinical criteria from the international consensus.",{"label":16,"type":10,"description":17,"interventionNames":10},"Cognitively Unimpaired","The Cognitively Unimpaired group refers to those participants without indications of cognitive impairment, including two subgroups: healthy controls and people with subjective cognitive decline",{"label":19,"type":10,"description":20,"interventionNames":10},"Other Dementias","The Other Dementias group includes participants diagnosed with forms of dementia other than dementia with Lewy bodies (e.g., Alzheimer's disease, Parkinson's disease dementia), as well as those with dementia not otherwise specified.",[22],{"name":23,"role":24,"phone":25,"phoneExt":10,"email":26},"Daniel Ferreira, Docent, Senior Lecturer","CONTACT","+46720128047","daniel.ferreira.padilla@ki.se",[28],{"facility":29,"status":30,"city":31,"state":10,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Karolinska University Hospital","RECRUITING","Stockholm","14157","Sweden","SE",{"type":36,"coordinates":37},"Point",[38,39],18.06871,59.32938,{"lat":39,"lon":38},[42],{"name":23,"role":24,"phone":25,"phoneExt":10,"email":26},{"type":44,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Daniel Ferreira","Associate Professor, Senior Researcher, Senior Lecturer","100639031","dementia-with-lewy-bodies-clinical-symptoms-biomarkers-and-progression-100639031",false,"NCT07629349","Dementia With Lewy Bodies: Clinical Symptoms, Biomarkers and Progression","Find-DLB","Inclusion Criteria:\n\n* At least one core clinical feature of dementia with Lewy bodies such as visual hallucinations, parkinsonism, cognitive fluctuations, or probable REM sleep behaviour disorder.\n\nExclusion Criteria:\n\n* Causes of cognitive impairment other than those related to dementia or MCI. Current or pass drug use.",true,"ALL",{"count":57,"type":58},600,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to improve the detection of dementia with Lewy bodies (DLB) and its prodromal phases, as well as advancing our current understanding of biological mechanisms and therapeutic options. The data is acquired at cognitive clinics in Stockholm (Sweden) and combined with national and international data to increase statistical power, representativeness and replication of results. Participants undergo collection of clinical assessments, neuroimaging and fluid biomarkers.",[62,63,16,19],"Dementia With Lewy Bodies (DLB)","Mild Cognitive Impairment (MCI)",[65,66,67],"case-control","retrospective","longitudinal","2026-06-04",{"date":70,"type":71},"2026-06-05","ACTUAL",{"date":73,"type":71},"2020-01-01",{"date":75,"type":58},"2031-03-01",{"name":5,"class":6},1]